These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19861227)

  • 1. Anti-angiogenesis agents in metastatic or recurrent cervical cancer.
    Monk BJ; Willmott LJ; Sumner DA
    Gynecol Oncol; 2010 Feb; 116(2):181-6. PubMed ID: 19861227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cervical cancer therapy: current, future and anti-angiogensis targeted treatment.
    Willmott LJ; Monk BJ
    Expert Rev Anticancer Ther; 2009 Jul; 9(7):895-903. PubMed ID: 19589029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer.
    Tambaro R; Scambia G; Di Maio M; Pisano C; Barletta E; Iaffaioli VR; Pignata S
    Crit Rev Oncol Hematol; 2004 Oct; 52(1):33-44. PubMed ID: 15363465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group.
    Tewari KS; Monk BJ
    Semin Oncol; 2009 Apr; 36(2):170-80. PubMed ID: 19332251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy for recurrent and metastatic cervical cancer.
    Tao X; Hu W; Ramirez PT; Kavanagh JJ
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 2):S67-71. PubMed ID: 18533239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study.
    Nezhat F; Wadler S; Muggia F; Mandeli J; Goldberg G; Rahaman J; Runowicz C; Murgo AJ; Gardner GJ
    Gynecol Oncol; 2004 Apr; 93(1):144-8. PubMed ID: 15047228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined-modality therapy of locally advanced cervical cancer.
    Rose PG
    J Clin Oncol; 2003 May; 21(10 Suppl):211s-217s. PubMed ID: 12743137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
    McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
    Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
    Zanetta G; Fei F; Mangioni C
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy for recurrent cervical cancer.
    Pectasides D; Kamposioras K; Papaxoinis G; Pectasides E
    Cancer Treat Rev; 2008 Nov; 34(7):603-13. PubMed ID: 18657909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer.
    Minion LE; Tewari KS
    Expert Rev Anticancer Ther; 2017 Mar; 17(3):191-198. PubMed ID: 27748633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cervical cancer: combined modality therapy.
    Grigsby PW
    Cancer J; 2001; 7 Suppl 1():S47-50. PubMed ID: 11504285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy for recurrent cervical cancer.
    Cadron I; Van Gorp T; Amant F; Leunen K; Neven P; Vergote I
    Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S113-8. PubMed ID: 17804044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin and pentoxifylline in advanced or recurrent squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group.
    Mannel RS; Blessing JA; Boike G
    Gynecol Oncol; 2000 Oct; 79(1):64-6. PubMed ID: 11006033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting angiogenesis in head and neck cancer.
    Seiwert TY; Cohen EE
    Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab for the treatment of cervical cancer.
    Bizzarri N; Ghirardi V; Alessandri F; Venturini PL; Valenzano Menada M; Rundle S; Leone Roberti Maggiore U; Ferrero S
    Expert Opin Biol Ther; 2016; 16(3):407-19. PubMed ID: 26796332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
    Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J
    Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Medical treatment of metastatic or recurrent cancer of the cervix].
    de la Motte Rouge T; Pautier P; Hamy AS; Duvillard P; Bruna A; Castaigne D; Morice P; Haie-Meder C; Lhommé C
    Bull Cancer; 2006 Mar; 93(3):263-70. PubMed ID: 16567313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of carboplatin and whole body hyperthermia (WBH) in recurrent and metastatic cervical cancer.
    Richel O; Zum Vörde Sive Vörding PJ; Rietbroek R; Van der Velden J; Van Dijk JD; Schilthuis MS; Westermann AM
    Gynecol Oncol; 2004 Dec; 95(3):680-5. PubMed ID: 15581981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenesis as a strategic target for prostate cancer therapy.
    Li Y; Cozzi PJ
    Med Res Rev; 2010 Jan; 30(1):23-66. PubMed ID: 19536866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.